1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS

Disclosed is a phenyl substituted 1, 2, 4-triazole of formula (I) where the substituents are as disclosed in the specification. Examples of compounds of formula (I) include: 4-{ 2-[1-(3,4-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-ylthio]ethyl} morpholine; 1-{ 2-[1-(3,4-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-yl-thio]ethyl} piperidine and 1-{ 2-[1-(3,4-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-ylthio]ethyl} pyrrolidine. Also disclosed is the use of a compound of formula (I) for treating a sigma-1 receptor mediated disease or condition selected from the group comprising diarrhoea, lipoprotein disorders, hyperlipidaemia, hypertriglyceridemia, hypercholesterolemia, obesity, migraine, arthritis, hypertension, arrhythmia, ulcer, glaucoma, learning, memory and attention deficits, cognition disorders, neurodegenerative diseases, demyelinating diseases, addiction to drugs and chemical substances including cocaine, amphetamine, ethanol and nicotine; tardive dyskinesia, ischemic stroke, epilepsy, stroke, stress, cancer, psychotic conditions, inflammation, autoimmune diseases and pain. Further disclosed is a process for preparing a compound of formula (I) and a pharmaceutical composition comprising a compound of formula (I).